Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

16 Feb 2020

• By Brenda Sandburg

A law book with a gavel - Constitution — Sanofi Says Unconstitutional Status Of PTAB Judges Warrants Appeal of Lantus Ruling

Related Content

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

16 Feb 2020

Biocon And Mylan's Fulphila And Insulin Plans On Track

27 Jan 2020

'Super Dramatic' Ruling On PTAB Judges' Unconstitutional Status Will Have 'Limited Fallout'

05 Nov 2019

Patent Judges Could Get Congressional Fix After Federal Circuit Ruling

21 Nov 2019

Mylan/Biocon’s Insulin Glargine Would Get A Respite Under US Budget Legislation

18 Dec 2019

US Supreme Court Seems Poised To Allow Patent Holders More Judicial Review Options

10 Dec 2019

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

27 Jan 2020

Related Companies

Sanofi

Viatris Inc.

Arthrex, Inc.

Smith & Nephew plc

Biocon, Ltd.

Additional Topics

Legal Issues Intellectual Property Policy BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.